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Background: The guanine nucleotide exchange factor Tiam1 regulates the activity of the small GTPase Rac1, a crucial
regulator of cell adhesion, proliferation, and survival.
Results: The SCFTrCP ubiquitin ligase in cooperation with CK1 targets Tiam1 for proteasome-dependent degradation.
Conclusion: Tiam1 degradation is required to terminate the mTOR-S6K signaling pathway.
Significance: Tiam1 degradation controls the duration of mTOR-S6K signaling in response to mitogens.
Tiam1 (T-cell lymphoma invasion and metastasis 1) is a gua-
nine nucleotide exchange factor that specifically controls the
activity of the smallGTPaseRac, a key regulator of cell adhesion,
proliferation, and survival. Here, we report that in response to
mitogens, Tiam1 is degraded by the ubiquitin-proteasome sys-
tem via the SCFTrCP ubiquitin ligase. Mitogenic stimulation
triggers the binding of Tiam1 to the F-box proteinTrCP via its
degron sequence and subsequentTiam1ubiquitylation andpro-
teasomal degradation. The proteolysis of Tiam1 is prevented by
TrCP silencing, inhibitionofCK1andMEK, ormutationof the
Tiam1 degron site. Expression of a stable Tiam1 mutant that is
unable to interact with TrCP results in sustained activation of
the mTOR/S6K signaling and increased apoptotic cell death.
We propose that the SCFTrCP-mediated degradation of Tiam1
controls the duration of the mTOR-S6K signaling pathway in
response to mitogenic stimuli.
Tiam1 is a ubiquitously expressed guanine nucleotide
exchange factor that specifically activates the Rho-like GTPase
Rac1 in response to growth factors and cell-substrate interac-
tion (1–3). It was originally identified in a retroviral insertional
mutagenesis screen for genes that confer invasive properties to
T-lymphoma cells (1). Thereafter, a plethora of studies have
demonstrated that Tiam1 controls different Rac-dependent
cellular processes, such as cell polarity, cell-matrix adhesion,
cell-cell adhesion, cell survival, and cell growth and prolifera-
tion. Hence, it does not come as a surprise that Tiam1 plays a
critical role in cancer development. Tiam1 deficiency in mice
protects against Ras-induced skin carcinogenesis and corre-
lates with increased apoptosis and reduced proliferation and
growth in keratinocytes (4). This is in agreement with in vitro
studies reporting that Tiam1 associates with GTP-bound Ras
through a Ras-binding domain and functions as an effector that
mediates Ras activation of Rac (4). However, the fewer skin
tumors developing in Tiam1 knock-out mice progress more
frequently to malignancy, indicating that loss of Tiam1 stimu-
latesmalignant conversion (4). Indeed, in vitro, Tiam1 is known
to promote the formation of adherens junctions and the induc-
tion of an epithelial-like phenotype in mesenchymal cells (5, 6)
and to be required for both the formation and maintenance of
cadherin-based adhesions (7).
Despite the importance of Tiam1 in cancer, little is known
about the regulation of Tiam1 protein levels in normal and
cancer cells.Here, we report that in response tomitogenic stim-
ulation, Tiam1 is targeted for proteasome-dependent degrada-
tion by the SCFTrCP ubiquitin ligase in cooperationwith casein
kinase 1 and the MEK/ERK pathway. We also show that ubiq-
uitin-dependent degradation of Tiam1 is required to terminate
the activation ofmTOR-S6K signaling in response tomitogenic
stimulation.
EXPERIMENTAL PROCEDURES
Cell Culture and Drug Treatments—HEK293, HEK293T,
T98G, and MDCK2 cells were cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen) with 10% FCS and 100 units/ml
penicillin-streptomycin. The following drugs were used:
MG132 (Peptide Institute; 10 M), D4476 (Sigma-Aldrich; 50
M), IC261 (Sigma-Aldrich; 50 M), cycloheximide (Sigma-
Aldrich; 100 M), PD0325901 (Sigma-Aldrich; 10 M), U0126
(Millipore; 10 M), Rac inhibitor III EHop-016 (Millipore; 50
M), and phorbol 12-myristate 13-acetate (Sigma-Aldrich; 10
ng/ml). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assays were carried according to the manufacturer’s
protocol.
Transient Transfections—Cells were transfected by the poly-
ethylenimine or liposome-mediated (Lipofectamine 2000;
Invitrogen) methods
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Plasmids—Full-length and N-terminally truncated (C1199)
human Tiam1 carrying a C-terminal HA tag cDNAs were cloned
by PCR into the EcoRV and NotI sites of pcDNA3. GFP-tagged
Tiam1was kindly provided by F. Zwartkruis. The full-length con-
structs were used as template to generate the Tiam1(S370A/
S374A), Tiam1(S414A/S418A), Tiam1(S329A/S334A), and Tiam1
(S329A/S334A/T340A) mutants using the QuikChange site-di-
rected mutagenesis kit (Stratagene) according to manufacturer’s
directions.Theoligonucleotidesusedwereasfollows:Tiam1(S370A/
S373A) forward primer, 5-CTTTGTGGGCAGCGACGCCG-
GCAGCAGCGCCACCGGGGATGCGGCTC-3; Tiam1(S370-
A/S373A) reverse primer, 5-GAGCCGCATCCCCGGTGGCG-
CTGCTGCCGGCGTCGCTGCCCACAAAG-3; Tiam1(S414-
A/S418A) forward primer 5-CAGCGATGAGCAGAGCGCCG-
GCACCCTGGCCTCTCCGGGCCAAGTCGGAC-3; Tiam1(S-
414A/S418A) reverse primer, 5-GTCCGACTTGGCCCGG-
AGAGGCCAGGGTGCCGGCGCTCTGCTCATCGCTG-3;
Tiam1(S329A/S334A) forward primer, 5-GGCGAGGGCGCT-
GAGTTTGCAGACGCTGGGATTGAAGGG-3; Tiam1(S329-
A/S334A) reverse primer, 5-CCCTTCAATCCCAGCGTCTG-
CAAACTCAGCGCCCTCGCC-3; Tiam1(S329A/S334A/T-
340A) forward primer, 5-GAGTTTGCAGACGCTGGGATTG-
AAGGGGCCGCTACCGACACG-3; and Tiam1(S329A/S334-
A/T340A) reverse primer, 5-CGTGTCGGTAGCGGCCCCTT-
CAATCCCAGCGTCTGCAAACTC-3. All constructs were
verified by sequencing.
Biochemical Methods—Extract preparation, immunopre-
cipitation, and immunoblotting were previously described (8).
Mouse monoclonal antibodies were from Invitrogen (Cul1),
Sigma-Aldrich (FLAG), Santa Cruz Biotechnology (Actin, p70-
S6K), Covance (HA), Cell Signaling Technology (phospho-Erk1/
2(Thr202/Tyr204)), and BD Biosciences (Rac1). Rabbit polyclonal
antibodieswere fromSantaCruzBiotechnology (Tiam1),Cell Sig-
naling Technology (TrCP1, Erk1/2, phospho-p70-S6K(Thr421/
Ser424), phospho-p70-S6K(Thr389), cleaved caspase-3(Asp175)),
Sigma-Aldrich (FLAG), and Torrey Pines Biolabs (GFP).
In Vitro Binding Assay—In vitro translated 35S-labeled
TrCP1 andFBXW5were incubatedwith proteinG-Sepharose
beads precoupled with the following Tiam1 synthetic pep-
tides: 327EGSEFADSGIEGAT340, 330EFADSGIEGATTDT343,
327EGpSEFADpSGIEGAT340, or 330EFADpSGIEGApTTDT343
for 2 h at 4 °C. The beads were washed four times with lysis
buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 250 mM NaCl,
0.1% Triton X-100, 50 mM NaF, 1 mM DTT, 0.1 mM Na3VO4).
Proteinswere elutedwith Laemmli buffer for 5min at 95 °C and
subjected to SDS-PAGE followed by autoradiography.
In Vitro Ubiquitylation Assay—Tiam1 ubiquitylation was
performed in a volume of 10 l containing SCFTrCP-Tiam1
immunocomplexes, 50 mM Tris, pH 7.6, 5 mM MgCl2, 0.6 mM
DTT, 2 mM ATP, 1.5 ng/l E1 (Boston Biochem), 10 ng/l
Ubc3, 2.5 g/l ubiquitin (Sigma-Aldrich), and 1 M ubiquitin
aldehyde. The reactions were incubated at 30 °C for 60min and
analyzed by immunoblotting.
Purification ofTrCP2 Interactors—HEK293T cells grown in
15-cm dishes were transfected with pcDNA3–2FLAG-
2HA-TrCP2 and treated with 10 M MG132 for 5 h. Cells
were harvested and subsequently lysed in lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet
P-40, 2 mM -glycerophosphate plus protease and phosphatase
inhibitors). TrCP2 was immunopurified with mouse anti-
FLAG M2-agarose resin (Sigma-Aldrich). After washing, pro-
teins were eluted by competition with FLAG peptide (Sigma-
Aldrich). The eluate was then subjected to a second immuno-
purification with anti-HA resin (12CA5 monoclonal antibody
cross-linked to protein G-Sepharose; Invitrogen) prior to elu-
tion in Laemmli sample buffer. The final eluate was separated
by SDS-PAGE, and proteins were visualized by colloidal Coo-
massie Blue. Bands were sliced out from the gels and subjected
to in-gel digestion. Gel pieces were then reduced, alkylated, and
digested according to a published protocol (9). For mass spec-
trometric analysis, peptides recovered from in-gel digestion
were separated with a C18 column and introduced by nano-
electrospray into the LTQOrbitrap XL (Thermo Fisher) with a
configuration as described (10). Peak lists were generated from
the MS/MS spectra using MaxQuant build 1.0.13.13 and then
searched against the IPI Human database (version 3.37, 69164
entries) using Mascot search engine (Matrix Science). Car-
baminomethylation (57Da) was set as fixedmodification and
protein N-terminal acetylation and methionine oxidation as
variable modifications. Peptide tolerance was set to 7 ppm, and
fragment ion tolerance was set to 0.5 Da, allowing two missed
cleavages with trypsin enzyme. Finally, Scaffold (version Scaf-
fold_3.6.1; Proteome Software Inc.) was used to validate
MS/MS-based peptide and protein identifications. Peptide identi-
fications were accepted if theirMascot scores exceeded 20.
Gene Silencing by Small Interfering RNA—The oligonucleo-
tides designed for targeting both TrCP1 and TrCP2 are as
follows: sense sequence, 5-GTGGAATTTGTGGAACATC
dTdT-3; and antisense sequence, 5-GATGTTCCACAAAT-
TCCACdTdT-3. Cells were transfected with the oligonucleo-
tides twice (24 and 48 h after plating) using Oligofectamine
(Invitrogen) according to the manufacturer’s recommenda-
tions. Forty-eight hours after the last transfection, lysates were
prepared and analyzed by immunoblotting.
Phosphorylation Analysis by Mass Spectrometry—Samples
were reduced with 10mMDTT for 30min at 60 °C, followed by
30-min incubation with iodoacetamide (20 mM) in the dark at
room temperature. The first digestion was performed using
Lys-C for 4 h at 37 °C. Subsequently, the digest was diluted 5-fold
using 50mMammoniumbicarbonate to a final urea concentration
of less than2M, anda seconddigestionwith trypsinwasperformed
overnightat37 °C.Finally, thedigestionwasquenchedby theaddi-
tion of formic acid to a final concentration of 0.1% (v/v). The
resulting solution was desalted using 200-mg Sep-Pak C18 car-
tridges (Waters Corporation), lyophilized, and reconstituted in
10% formic acid. LC-MSMS was performed with higher energy
collisiondissociated inaQ-ExactivePlusOrbitrap instrument.MS
spectra topeptide sequenceassignmentwereperformedwithPro-
teomeDiscoverer version 1.4 andMASCOT version 2.4 as search
engine. The localization of phosphorylated sites was evaluated
with PhosphoRS version 3 (11).
Rac Activity Assay—The abundance of GTP-bound Rac1 was
determined as follows. Cells were lysed in lysis buffer (10 mM
Tris, 150mMNaCl, 50mMMgCl2, 0.5%Nonidet P-40) contain-
ing 2 g of biotinylated p21-binding domain of Pak1. The
cleared supernatantwas then incubatedwith streptavidin beads
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for 30 min at 4 °C. Beads were washed, and GTP-bound Rac1
was analyzed by immunoblotting with an anti-Rac1 antibody
(Upstate Biotechnology Inc.).
RESULTS
Tiam1 Interacts with TrCP—In an attempt to identify new
targets of the SCFTrCP ubiquitin ligase, we expressed TrCP
with an N-terminal FLAG-HA epitope tag in HEK293T cells
and purified FLAG-HA-TrCP immunoprecipitates, which
were then analyzed by mass spectrometry. In two independent
immunopurifications, peptides corresponding toTiam1 (T-cell
lymphoma invasion andmetastasis 1) were recovered (Fig. 1A).
Conversely, when we immunopurified Tiam1 from HEK293T
cells, we identified peptides corresponding to TrCP (Fig. 1B).
To confirm the binding between TrCP and Tiam1 and test
its specificity, we overexpressed different FLAG-tagged
F-box proteins (all containing WD40 repeats) in HEK293T
cells. We then carried out FLAG immunoprecipitations to
examine the interaction with endogenous Tiam1. TrCP1
and its paralog TrCP2 were the only proteins able to coim-
munoprecipitate with Tiam1 (Fig. 1C). The coimmunopre-
cipitation of endogenous TrCP with exogenously expressed
Tiam1was confirmed by immunoprecipitation coupled to immu-
noblotting (Fig. 1D).
It has been shown that substitution to alanine of Arg474 in
TrCP1 (or Arg447 in TrCP2) within its WD40 -propeller
structure disrupts TrCP interaction with the substrate (8, 12).
To assess whether the interaction between Tiam1 and
TrCP is mediated by the TrCP WD40 -propeller, we
immunoprecipitated FLAG-tagged wild type TrCP2 and
the TrCP2(R447A) mutant from HEK293T cells and exam-
ined their binding to endogenous Tiam1. As shown in Fig.
FIGURE 1. Tiam1 interactswith and is ubiquitylated by the SCFTrCP ubiquitin ligase. A, peptide coverage of Tiam1 in themass spectrometry analysis
of TrCP2 immunopurification. Amino acid sequences of detected Tiam1 peptides are highlighted in yellow. B, peptide coverage of TrCP2 (also known
as FBXW11) in the mass spectrometry analysis of Tiam1 immunopurification. Amino acid sequences of detected TrCP2 peptides are highlighted in
yellow. C, the indicated FLAG-tagged F-box proteins containing WD40 repeats (FBXWs) or an empty vector (EV) were expressed in HEK293T cells.
Forty-eight hours after transfection, cells were treated for 5 h with the proteasome inhibitors MG132, then harvested, and lysed. Whole cell extracts
(WCE) were immunoprecipitated (IP) with anti-FLAG antibody and immunoblotted with antibodies specific for the indicated proteins. D, HEK293T cells
were transfected with GFP-tagged wild type Tiam1 or an empty vector. Cells were collected and lysed. Tiam1 was immunoprecipitated from whole cell
extracts, and immunocomplexes were analyzed by immunoblotting with antibodies specific for the indicated proteins. E, arginine 447 in the WD40
repeat of TrCP2 is required for the interaction with Tiam1. HEK293T cells were transfected as indicated and analyzed as in C. F, Tiam1, Skp1, Cul1, and
Rbx1 were expressed in HEK293T in the absence or presence of TrCP1 or an inactive TrCP1-F-box mutant. After immunopurification with anti-FLAG
resin, an in vitro ubiquitylation assay of Tiam1 was performed. Samples were analyzed by immunoblotting with an anti-Tiam1 antibody. The bracket
indicates a ladder of bands corresponding to polyubiquitylated Tiam1.
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1E, wild type TrCP coimmunoprecipitated with Tiam1,
whereas the TrCP2(R447A) mutant did not.
These results suggest that Tiam1 is a substrate of SCFTrCP.
To test whether SCFTrCP targets Tiam1 for ubiquitin conjuga-
tion, we reconstituted the ubiquitylation of Tiam1 in vitro.
TrCP1, but not an inactive TrCP1(F box) mutant, was
indeed able to efficiently ubiquitylate Tiam1 (Fig. 1F).
The Interaction of Tiam1 with TrCP Requires a Conserved
Phosphodegron—Substrates of SCFTrCP share a conserved
DSGXX(X)S degron that is bound by TrCP (13–16). Two
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FIGURE 2. Phosphorylation of Ser329, Ser334, and Thr340 in Tiam1 is required for its interaction withTrCP1. A, schematic representation of Tiam1 functional
domains and three putative TrCP-bindingmotifs. B, HEK293T cells were transfected with FLAG-tagged TrCP1 and either HA-taggedwild type Tiam1, HA-tagged
Tiam1(S370A/S374A), HA-tagged Tiam1(S414A/S418A), or an empty vector (EV). Forty-eight hours after transfection, cells were harvested and lysed. Whole cell
extractswere subjected to immunoprecipitation (IP)with anti-HA resin, followedby immunoblottingwith antibodies specific for the indicatedproteins.C, alignment
of theaminoacid regions corresponding to theTrCP-bindingmotifs inTiam1orthologsandpreviously reportedTrCPsubstrates, i.e. IB, Emi1,-catenin,Claspin,
andCdc25A. The amino acidic sequences of the phosphodegronmutants are shownbelow.D, HEK293T cellswere transfectedwith FLAG-taggedTrCP1 and either
HA-taggedwild type Tiam1, HA-tagged Tiam1(S329A/S334A), HA-tagged Tiam1(S329A/S334A/T340A), or an empty vector. Forty-eight hours after transfection, the
cellswereharvestedand lysed.Wholecell extractsweresubjectedto immunoprecipitationwithanti-FLAGresin, followedby immunoblottingwithantibodiesspecific
for the indicatedproteins.E, HEK293Tcellswere transfectedwithanemptyvector,HA-taggedwild typeTiam1,orHA-taggedTiam1(S329A/S334A). Forty-eighthours
after transfection, cells were harvested and lysed. Whole cell extracts were subjected to immunoprecipitation with anti-HA resin and then immunoblotted with
antibodies specific for the indicated proteins. When indicated, immunocomplexes were incubated with lambda phosphatase (PP) for 30 min and then washed. F,
HEK293Tcellswere transfectedwithHA-taggedwild typeTiam1,HA-taggedTiam1(S329A/S334A), orHA-taggedTiam1-C1199.Whole cell extractswere subjected to
immunoprecipitation and immunoblotting as in E. G, HEK293T cells were transfected with GFP-tagged wild type Tiam1 or GFP-tagged Tiam1-C1199. Cells were
collected and lysed.TrCPwas immunoprecipitated fromwhole cell extracts, and immunocomplexeswere analyzedby immunoblottingwith antibodies specific for
the indicated proteins. H and I, 35S-TrCP1 and 35S-FBXW5were transcribed/translated in vitro and incubated with beads coupled to peptides spanning the Tiam1
degron. Beads were washed with Triton-X buffer, and bound proteins were eluted and subjected to electrophoresis and autoradiography. The last two lanes
correspond to 10% of the in vitro translated protein inputs. Peptide sequence spanning the Tiam1 degron is shown on the left. J–L, FLAG-HA-tagged Tiam1 was
immunopurified fromHEK293T cells and analyzed bymass spectrometry. Ion fragmentation spectra are shown. The indicated Tiam1 tryptic peptides spanning the
phosphodegronwere foundphosphorylatedonSer329 (J), Ser334 (K), or Thr341 (L). As shown,peptide sequencescanbeexplainedby their respectivecollision-induced
dissociationMS/MS spectra including Ser(P)329, Ser(P)334, and Thr(P)341.
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potential degronmotifs are present at theN terminus of human
Tiam1, namely, 369DSGSSS374 and 413SSGTLS418 (Fig. 2A). To
test which of these motifs is responsible for the interaction of
Tiam1 with TrCP, we generated a number of mutants in
which either Ser370/Ser374 or Ser414/Ser418 were replaced by
alanine and evaluated the ability of these mutants to coimmu-
noprecipitate with TrCP. Fig. 2B shows that wild type Tiam1,
Tiam1(S370A/S374A), and Tiam1(S414A/S418A) were all able
to bind TrCP, indicating that these serine residues do not
mediate the interaction of Tiam1 with TrCP. We then tested
the requirement of a third putative Tiam1 degron motif, i.e.
329SEFADSGIEGAT340 (Fig. 2A), for the binding of Tiam1 to
TrCP. The upstream Ser329 resembles the serine residue in
Cdc25A (Ser79 preceding the conserved aspartate) whose phos-
phorylation is required for Cdc25A binding to TrCP (Fig. 2C
andRefs. 17–19).We generatedTiam1mutants inwhich Ser329
and Ser334 residues, alone or in combination with Thr340, were
replaced by alanine. These Tiam1mutants were not able to pull
down exogenous (Fig. 2D) or endogenous (Fig. 2E) TrCP in
immunoprecipitation experiments. Of note, treatment of
Tiam1 immunocomplexes with -phosphatase disrupted its
binding to TrCP (Fig. 2E). Moreover, a Tiam1 mutant trun-
cated at the N terminus (C1199) lacking the TrCP degron (5)
did not coimmunoprecipitate with endogenous TrCP (Fig. 2,
FIGURE3.Proteasome-andTrCP-dependentdegradationofTiam1 in response tomitogens.A, HEK293 cells, cultured in lowserum for 48h,were treated
with PMA. Cells were collected at the indicated times and lysed. Whole cell extracts were subjected to immunoblotting with antibodies specific for the
indicated proteins. Actin is shown as a loading control. B, HEK293 cells were treatedwith PMA as in Awith or without the proteasome inhibitor MG132. Whole
cell extracts were analyzed as in A. C, HEK293 cells were either cultured in presence of serum (S) or deprived of serum for 48 h (SD). After serum readdition, the
cells were collected at the indicated times. When indicated, the proteasome inhibitor MG132 was added. Protein extracts were analyzed by immunoblotting
with antibodies specific for the indicated proteins. Cul1 is shown as a loading control.D and E, T98G cells (D) andMDCK cells (E) were treated with PMA as in A
and with MG132 when indicated. Whole cell extracts were analyzed as in A. F, HEK293 cells were transfected with the indicated siRNA oligonucleotides and
treated as in A. Cul1 is shown as loading control (CTR).G, HEK293 cells were transfectedwith FLAG-taggedTrCP1-F or an empty vector (EV) and treatedwith
PMA for 2h. Cellswere collected and lysed.Whole cell extractswere analyzedas inA.H, HEK293were transfectedwith anempty vector or FLAG-taggedTrCP1.
Forty-eight hours after transfection, cells were treated with MG132 and PMA for 5 h (when indicated), then harvested, and lysed. Whole cell extracts were
immunoprecipitated (IP) with anti-FLAG resin and immunoblotted with anti-Tiam1 and anti-FLAG antibodies.
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F and G). Taken together, these results demonstrate that the
association of Tiam1 with TrCP requires the conserved
degron motif SEFADSGIEGAT.
As a second approach to examine whether phosphorylation
of Tiam1 is required for the interaction with TrCP, we
employed an in vitro binding assay using immobilized synthetic
phosphopeptides containing the TrCP recognition domain of
Tiam1. Peptides containing phosphorylated residues at posi-
tions Ser329 and Ser334 (Fig. 2H) or at positions Ser334 and
Thr340 (Fig. 2I) efficiently associated with in vitro-translated
TrCP (but not with FBXW5), whereas the unphosphorylated
peptides did not. These results indicate that phosphorylation of
Ser329, Ser334, and Thr340 directly mediates the interaction of
Tiam1 with TrCP.
To test whether the Tiam1 degron is phosphorylated in cells,
FLAG-HA epitope-tagged Tiam1 immunoprecipitated from
HEK293T cells was subjected to tryptic digestion followed by
phosphopeptide enrichment by Ti4-IMAC and LC-MS/MS
FIGURE 4. CK1 and the MAPK pathway control the TrCP-mediated degradation of Tiam1. A, HEK293T cells were transfected with FLAG-tagged
CK1, FLAG-tagged TrCP1, or an empty vector. Forty-eight hours after transfection, cells were treated with MG132 for 5 h. Cells were then harvested
and lysed. Whole cell extracts were immunoprecipitated (IP) with anti-FLAG resin and immunoblotted with antibodies specific for the indicated
proteins. B and C, Tiam1 was immunopurified and dephosphorylated with lambda phosphatase prior to an in vitro kinase assay in the presence of
purified CK1. A mock reaction (no kinase) was used as a negative control. Individual mixes were subsequently trypsinized and analyzed by mass
spectrometry. The Tiam1 tryptic peptide TTQDVNAGEGSEFADSGIEGATTDTDLLSR was not found to be phosphorylated in the negative control (B). When
CK1 was used in the in vitro kinase assay, the same peptide was found to be phosphorylated on Ser329 (C). As shown, both peptide sequences can be
clearly explained by their respective HCDMSMS spectrum (Mascot score 139 and 92), including the Ser(P)329 site (PhosphoRS site probability 100.0%).
In these figures, pS denotes phosphorylated serine, b denotes b ions, and y denotes y ions. D, HEK293T cells were transfected with FLAG-tagged TrCP1.
Forty-eight hours after transfection, cells were treatedwithMG132 for 5 h (when indicated) in the presence or absence of the indicated kinase inhibitors.
Cells were then harvested and lysed. Whole cell extracts were immunoprecipitatedwith anti-FLAG resin and immunoblottedwith antibodies specific for
the indicated proteins. E, HEK293T cells were transfected with HA-tagged wild type Tiam1 or HA-tagged Tiam1(S329A/S334A). Forty-eight hours after
transfection, cells were treated as inD. Whole cell extracts were processed as inD except that an anti-HA resin was used for immunoprecipitation. F, cells
were treated with PMA for 4 h with or without the CK1 inhibitor D4476. Whole cell extracts were analyzed by immunoblotting. G, HEK293 cells were
transfected with plasmids expressing HA-tagged wild type Tiam1 along with plasmids expressing the indicated kinases. Twenty-four hours after
transfection, cells were collected and lysed. Whole cells extracts were analyzed by immunoblotting with antibodies specific for the indicated proteins.
H, HEK293T cells were transfected with either HA-tagged wild type Tiam1 or HA-tagged Tiam1(S329A/S334A) along with Myc-tagged ubiquitin with or
without CK1. Cells were harvested and lysed in 0.1% Triton X-100 lysis buffer. Whole cell extracts were denatured by adding 1% SDS and boiling for 10
min. SDS was quenched and diluted. Whole cell extracts were then immunoprecipitated with anti-HA resin and immunoblotted with anti-Myc antibod-
ies. The bracket indicates a ladder of bands corresponding to polyubiquitylated Tiam1. I, HEK293 cells were treated with PMA in the absence or presence
of the indicated compounds. Cells were collected at the indicated times and lysed. Whole cell extracts were analyzed by immunoblotting. J, HEK293T
cells were transfectedwith FLAG-taggedTrCP1 or FLAG-taggedTrCP1(R474A). Forty-eight hours after transfection, cells were treatedwithMG132 for
5 h in the presence or absence of the MEK inhibitor U1026. Cells were then harvested and lysed. Whole cell extracts were immunoprecipitated with
anti-FLAG resin and immunoblotted with antibodies specific for the indicated proteins. EV, empty vector.
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analysis. We recovered phosphopeptides containing Ser(P)329
(Fig. 2J), Ser(P)334 (Fig. 2K), and Thr(P)341 (Fig. 2L), indicating
that the Tiam1 degron is phosphorylated in cultured cells.
Mitogens Induce the Degradation of Tiam1—Tiam1-Rac sig-
naling controls a wide range of signaling pathways regulated by
extracellular signals. While testing the effect of diverse stimuli
on the abundance of Tiam1, we observed a decrease of Tiam1
levels in HEK293 cells treated with the potent mitogen phorbol
12-myristate 13-acetate (PMA; Fig. 3A). Mitogen-induced
down-regulation of Tiam1 is transient because Tiam1 abun-
dance goes back approximately to the initial levels 10–16 h
after PMA treatment. The reduction in Tiam1 levels was pre-
vented when cells were treated with the proteasome inhibitor
MG132, indicating that Tiam1degradation in response to PMA
is mediated by the proteasome (Fig. 3B). Similarly, Tiam1 pro-
tein levels decreased in a proteasome-dependent manner in
HEK293 cells thatwere first deprived of serum for 48 h and then
stimulated by the readdition of serum (Fig. 3C). The degrada-
tion of Tiam1 in response to mitogenic stimulation was
observed also in other cell types, namely T98G cells (Fig. 3D)
and MDCK cells (Fig. 3E).
Next, we examined whether the observed mitogen-induced
degradation of Tiam1 is mediated by TrCP. We silenced by
RNAi the expression of both TrCP1 and TrCP2 (20–24) in
HEK293 cells, which were then treated with PMA. As shown in
Fig. 3F, TrCP knockdown inhibited the PMA-induced degra-
dation of Tiam1. Ectopic expression of TrCP with a deleted
F-box motif (TrCP-F), which has been shown to function as
a dominant negativemutant (25–29), also prevented the degra-
dation of Tiam1 (Fig. 3G). Moreover, the binding of TrCP to
endogenous Tiam1 was enhanced by PMA treatment (Fig. 3H).
Altogether, these results indicate that mitogenic stimulation of
cells triggers the TrCP-mediated proteasomal degradation of
Tiam1.
Casein Kinase 1 and MAPK Signaling Control the TrCP-
mediated Degradation of Tiam1—In the Tiam1 immunopurifi-
cation described above, we also retrieved three peptides (DIK-
PDNFLMGIGR, MSTPVEVLCK, and AAQQAASSSGQGQ-
QAQTPTGK) corresponding to casein kinase 1 (CK1) and
one peptide (HPQLHIESK) corresponding to casein kinase 1
(CK1). First, we confirmed the interaction betweenTiam1 and
CK1 (Fig. 4A). Second, to test whether CK1 is able to phos-
phorylate the Tiam1 degron and pinpoint the specific Tiam1
site targeted by CK1, immunopurified, dephosphory-
lated Tiam1 was subjected to an in vitro kinase assay in the
presence or absence of purified CK1 prior to mass spectrom-
FIGURE 5. Tiam1 degradation controls the duration of themitogen-inducedmTOR-S6K signaling pathway. A, HEK293 cells expressing HA-tagged
wild type Tiam1, HA-tagged Tiam1(S329A/S334A), or HA-tagged Tiam1-C1199 were incubated in low serum for 24 h and then treated with PMA and
cycloheximide (CHX) for the indicated times. Cells were collected and lysed. Whole cell lysates were analyzed by immunoblotting with an anti-HA
antibody. Actin is shown as a loading control. The graph shows the quantification of Tiam1 abundance relative to the amount at time 0. B, HEK293 cells
transduced with retroviruses expressing HA-tagged wild type Tiam1 or HA-tagged Tiam1(S329A/S334A) were incubated in low serum for 48 h and then
treated with PMA. At the indicated times, cells were collected and lysed. Whole cell extracts were analyzed by immunoblotting with antibodies for the
indicated proteins. Levels of GTP-loaded Rac1 were analyzed in a pulldown assay as described under “Experimental Procedures.” Actin is shown as
loading control. To facilitate comparison, a dotted line separates samples from cells expressing wild type Tiam1 and samples from cells expressing
Tiam1(S329A/S334A). C, whole cell lysates of asynchronously growing HEK293 cells expressing HA-tagged wild type Tiam1 or HA-tagged Tiam1(S329A/
S334A) were analyzed by immunoblotting with antibodies for the indicated proteins.D, as in B except that serum (instead of PMA) was used as mitogen.
Cul1 is shown as loading control. E, HEK293 cells were incubated in low serum for 48 h and then treated with PMA. Six hours after PMA treatment, cells
were analyzed by immunoblotting. Rac1 activity was assessed as in B.
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etry analysis. We identified phosphopeptides containing
Ser(P)329 in CK1-treated Tiam1 samples (Fig. 4, B and C).
These phosphopeptides were not found in Tiam1 treated with
other kinases or when no kinase was added to the reaction.
Next, we assessed the possible involvement of CK1 in the
TrCP-dependent degradation of Tiam1. We employed the
CK1 pharmacological inhibitors D4476 and IC261 to inactivate
CK1 inHEK293T cells. As shown in Fig. 4 (D andE), theTiam1-
TrCP binding was abolished by both D4476 and IC261, sug-
gesting that CK1 is required for the TrCP-dependent degra-
dation of Tiam1. Indeed, pharmacological inhibition of CK1
prevented the degradation of Tiam1 in response to PMA treat-
ment (Fig. 4F). Accordingly, in cultured cells, Tiam1 degrada-
tion (Fig. 4G) and ubiquitylation (Fig. 4H) were stimulated by
the ectopic expression of CK1.
The finding that mitogens induce the CK1- and TrCP-me-
diated degradation of Tiam1 prompted us to test whether
MAPKs control Tiam1 proteolysis. Fig. 4I shows that pharma-
cological inhibition ofMEK1 andMEK2, two protein kinases of
theMAPK cascade known to be activated bymitogenic stimuli,
blocked the PMA-induced degradation of Tiam1 to the same
extent of MG132. Accordingly, inhibition of MEK1 and MEK2
reduced the interaction between TrCP and Tiam1 (Fig. 4J).
Tiam1 Degradation Is Required for the Termination of
mTOR-S6K Signaling—To investigate the biological signifi-
cance of Tiam1 degradation, physiological levels of wild type
Tiam1 and the Tiam1(S239A/S334A) mutant were expressed
in HEK293 cells. Tiam1(S239A/S334A) and the Tiam1 mutant
truncated at the N terminus (C1199) lacking the TrCP bind-
ing domain were resistant to the degradation induced by mito-
genic stimulation, as indicated by the half-life experiment
shown in Fig. 5A.
Because it has been shown that both Tiam1 and Rac1 control
the mTOR-S6K signaling pathway, which mediates the mito-
genic response in cells (30–32), we analyzed the activation of
mTOR-S6K signaling in response to mitogenic stimulation in
cell expressing wild type Tiam1 and the nondegradable
Tiam1(S239A/S334A) mutant. As shown in Fig. 5B, mitogenic
stimulation of cells expressing wild type Tiam1 resulted in an
increase of the mTOR-mediated phosphorylation of p70-S6K
(Thr389) and its isoform p85-S6K (Thr412), which then rapidly
decreased. In contrast, cells expressing the nondegradable
Tiam1(S239A/S334A)mutant displayed a sustained (at least up
to 5 h after PMA treatment) phosphorylation of p70-S6K
(Thr389) and p85-S6K (Thr412) in response to mitogenic stim-
ulation. No remarkable effect on the phosphorylation of p70-
S6K (Thr389) and p85-S6K (Thr412) was observed in asyn-
chronously growing cells (Fig. 5C). The expression of the
degradation-resistant Tiam1(S239A/S334A) mutant had a
similar effect on the mitogen-induced activating phospho-
rylation of additional residues of p70-S6K (Thr421/Ser424)
and p85-S6K (Thr444/Ser447) (Fig. 5B). Similar results were
FIGURE 6. Inhibition of Tiam1 degradation results in loss of cell viability and increased apoptosis. A and B, HEK293 cells (A) or MDCK cells (B) transfected
with HA-tagged wild type Tiam1, HA-tagged Tiam1(S329A/S334A), or HA-tagged Tiam1-C1199 were incubated in low serum for 24 h and then treated with
PMA for 6 h. Cell viability was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The results are the averages of three indepen-
dent experiments. The error bars represent S.D. C, MDCK cells as in Bwere incubated in low serum for 24 h and then treated with PMA for the indicated times.
The cells were collected, lysed, and analyzed by immunoblotting with antibodies for the indicated proteins. D, as in C except that cells were fixed, stained for
cleaved caspase 3, and analyzed by flow cytometry. The results are the averages of three independent experiments. The error bars represent S.D.
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obtained when serum was used to stimulate cells expressing
wild type Tiam1 or the Tiam1(S239A/S334A) mutant (Fig.
5D). In agreement with previous reports (30), pharmacolog-
ical inhibition of Rac activity prevented the induction of S6K
phosphorylation following mitogenic stimulation, suggest-
ing that the mitogen-induced activation of the mTOR-S6K
signaling pathway is dependent on Rac activity (Fig. 5E).
Taken together, these results demonstrate that failure to
degrade Tiam1 in response to mitogens results in prolonged
activation of the mTOR/S6K signaling.
Failure to Degrade Tiam1Results in Loss of Cell Viability and
Increased Apoptosis—Finally, we investigated the effect of
defective degradation of Tiam1 on cell growth and survival.
After mitogenic stimulation, cells expressing Tiam1(S239A/
S334A) or Tiam1-C1199 displayed reduced cell viability when
compared with cells expressing wild type Tiam1 (Fig. 6, A and
B). Moreover, failure to degrade Tiam1 resulted in apoptotic
cell death as shown by the induction of the cleaved active form
of Caspase 3 (Fig. 6, C and D).
DISCUSSION
Here we have shown that Tiam1 is a novel substrate of the
SCFTrCP ubiquitin ligase, identified a conserved phosphode-
gron at the N terminus of Tiam1 that is required for Tiam1
binding to TrCP, and demonstrated that SCFTrCP targets
Tiam1 for proteasome-dependent degradation in response to
mitogenic stimulation. We have also found that the mitogen-
induced degradation of Tiam1 is mediated by CK1, which
phosphorylates a residue within the Tiam1 phosphodegron.
Tiam1 destruction is required for terminating the activation of
the mTOR-S6K signaling pathway following mitogenic stimu-
lation. Indeed, expression of a Tiam1 mutant unable to bind
TrCP results in sustained phosphorylation of S6K, a substrate
of mTOR. Failure to degrade Tiam1 leads to loss of cell via-
bility caused by increased apoptosis. Interestingly, it has
been recently reported that constitutive mTOR-S6K signal-
ing sensitizes cells to p53-dependent cell death in response
to stress conditions (33). In agreement with these studies, a
recent report has shown that cells expressing the degrada-
tion-resistant Tiam1-C1199 mutant are more sensitive to
DNA-damaging drug-induced apoptosis (34).
We have shown that the TrCP-mediated degradation of
Tiam1 is blocked by pharmacological inhibition of MEK.
Accordingly, the Malliri group (35) has demonstrated that
ERK1 and ERK2 associate with Tiam1 and that ERK activation
is required for the v-Src-induced degradation of Tiam1. The
involvement of the MEK-ERK pathway in the destruction of
Tiam1 via TrCP also suggests that the MEK-ERK-dependent
phosphorylation of Tiam1 could prime the phosphorylation of
the Tiam1 degron by CK1, as has been shown for other TrCP
substrates (16) (36, 37). Phospho-specific antibodies against the
Tiam1 degronmotif (329pSEFADpSGIEGApT340) are required to
test(both invitroandinculturedcells)whetherTiam1isphosphor-
ylated by CK1 on its degron following initial phosphorylation by
MEK-ERK on different sites. In conclusion, the finding that the
degradation of Tiam1, induced by CK1 in cooperation with the
MAPK cascade, is needed to terminatemTOR-S6K signaling sug-
gests a newmechanism by which theMAPK cascade controls the
timing of activation of the mTOR-S6K signaling pathway.
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